Ovometra-2.5 is a medical formulation that consists of Letrozole 2.5mg which is an oral non-steroidal aromatase inhibitor. It is designed for use in the management of particular hormone dependent medical conditions specifically certain types of hormone receptor positive breast cancer in postmenopausal women. Letrozole works by lowering the production of estrogen in the body that can help in slowing or preventing the growth of estrogen dependent cancer cells.
Composition
Each Ovometra-2.5 tablet consists of:
Letrozole 2.5 mg
Letrozole comes from a class of medicines which is called aromatase inhibitors. Aromatase is an enzyme which is responsible for changing certain hormones into estrogen. By preventing this enzyme, Letrozole lowers the estrogen levels in the body. This estrogen reducing effect forms the foundation of its therapeutic action in hormone-sensitive conditions.
Uses and Therapeutic Benefits
Ovometra-2.5 may be advised for the treatment of hormone receptor-positive breast cancer in postmenopausal women. Letrozole 2.5mg may be used as adjuvant therapy after primary treatment.
The medicine should be used only for symptoms accessed by a qualified healthcare professional. Treatment decisions may rely on factors like the patient’s medical history and menopausal status along with cancer characteristics and overall health.
How Letrozole Works?
Letrozole selectively inhibits the aromatase enzyme, resulting in decreased estrogen biosynthesis. In postmenopausal women, estrogen is produced primarily through the conversion of androgens into estrogens in peripheral tissues. By reducing this conversion, Letrozole lowers estrogen availability and helps reduce hormonal stimulation of estrogen-dependent cancer cells.
Dosage and Administration
The recommended dosage of Letrozole for its approved breast-cancer indications is generally 2.5 mg once daily, or as directed by the treating physician. Ovometra-2.5 can usually be taken orally with or without food. Patients should take the medicine at the prescribed dose and for the duration recommended by their healthcare professional. A missed dose should be handled according to the physician’s or product-label instructions.
Safety and Precautions
Ovometra-2.5 is a prescription medicine and should be used under appropriate medical supervision. Letrozole is not intended for use during pregnancy and may cause fetal harm. Patients should inform their healthcare provider about existing medical conditions and all medicines or supplements they are taking before starting treatment.
Possible adverse effects may include joint or muscle discomfort, fatigue, dizziness, headache, hot flushes, increased sweating, nausea, and changes in bone mineral density. Long-term treatment may require appropriate monitoring of bone health and other relevant clinical parameters.
Conclusion
Ovometra-2.5 (Letrozole 2.5 mg) is an aromatase inhibitor formulation intended for patients who require estrogen-lowering therapy for appropriate hormone-sensitive conditions. With its established mechanism of action and clinical applications, Letrozole remains an important therapeutic option in the management of hormone receptor-positive breast cancer. Ovometra-2.5 should be taken strictly according to the prescription and guidance of a qualified healthcare professional.
